China lifts price caps on 1,500 drugs

05/11/2014 | Reuters

China's National Development and Reform Commission lowered from more than 2,000 to about 500 the number of drugs considered critical to health and subject to low-price caps. The commission noted that low prices have limited manufacturers' ability to absorb rising costs and caused shortages of some medicines. The commission has not announced the results of its yearlong investigation into the pricing practices of Chinese and international pharmaceutical firms.

View Full Article in:


Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Attorney
Blue Cross Blue Shield of Louisiana
Baton Rouge, LA
Senior or Principal Consultant
PAREXEL International
Nationwide, SL_Nationwide
Chief Financial Officer
Health Alliance Plan of Michigan
Southfield, MI
Senior Vice-President Managed Care Mid-Atlantic Region
Mercy Health System
Conshohocken, PA
Associate Chief Financial Officer
Commonwealth Care Alliance
Boston, MA